A chemical used in pharmaceuticals, batteries or cosmetics can also be used to manufacture illicit drugs. The EU Council’s November 4 negotiating position proposes different controls for chemicals with legitimate industrial uses and substances designed primarily for illicit production. The mandate is a negotiating position; it creates no new compliance obligation today.
What would change for suppliers?
The proposed framework would consolidate the EU’s precursor rules, tighten restrictions on designer precursors and introduce a digital import system. The Council proposes allowing only limited uses of designer precursors, while streamlining procedures for legitimate trade in other covered substances.
One proposal has particular relevance for Canadian exporters: non-EU companies seeking to make covered precursors available in the EU internal market would appoint a single EU representative responsible for obtaining licences and meeting compliance obligations on their behalf. The scope and wording may change as the legislation proceeds.
What counsel can review now
Companies can identify which products could fall within the proposed categories, who holds the relevant licences today, and which entity supplies the information customs authorities need. Where a distributor or importer handles those tasks, counsel can assess whether existing contracts would accommodate a separate representative role if the final text requires one.
The policy challenge is to catch substances designed to evade controls without imposing avoidable costs on manufacturers that depend on legitimate inputs. The next text to compare with the Council mandate is the European Parliament’s position and, ultimately, any agreed regulation. Until then, the Council’s proposal is useful for planning, while existing rules govern shipments.
Source: Council of the EU release and negotiating mandate links, November 4.